Tx Delay Impacts Microvascular Reperfusion in STEMI

Share this content:
Tx Delay Impacts Microvascular Reperfusion in STEMI
Tx Delay Impacts Microvascular Reperfusion in STEMI

MONDAY, Jan. 4, 2016 (HealthDay News) -- For patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), delayed reperfusion therapy is associated with greater microcirculation injury, according to a study published in the Dec. 28 issue of JACC: Cardiovascular Interventions.

Abhiram Prasad, M.D., from Mayo Clinic in Rochester, Minn., and colleagues examined the effect of treatment delay on microvascular reperfusion in STEMI patients from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction trial. Resolution of ST-segment elevation (STR) and the myocardial blush grade (MBG) were used to examine the effect of symptom onset-to-balloon time (SBT) and door-to-balloon time (DBT) on myocardial reperfusion during primary PCI for 2,056 patients.

The researchers found that patients with longer SBT more often had absent microvascular perfusion (MBG 0/1) and STR <30 percent after primary PCI; this was observed for patients with low and high clinical risk profiles. SBT, anterior infarction, reference vessel diameter, lesion minimum lumen diameter, hyperlipidemia, and current smoking were independent predictors of MBG 0/1 in multivariable analysis; independent predictors of absent STR included SBT, anterior infarction, and history of renal insufficiency. DBT was found to be an independent predictor of MBG 0/1. Patients with increased three-year mortality were identified by MBG 0/1 and STR <30 percent.

"The present study suggests that delay in mechanical reperfusion therapy during STEMI is associated with greater injury to the microcirculation," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths